Search for content, post, videos

SmartCella raises 328 million SEK

Staffan Holmin

SmartCella Holding has announced the raising to further advance and accelerate the development of core technologies in the company’s three business units, Procella Therapeutics, Smartwise and SvedMed Solutions.

The financing, led by advisor SEB, brings together a renowned group of investors with AMF, SEB Pension, Alto Cumulus and Celox joining existing investors including AP4 and the founders Prof. Kenneth Chien, Thomas von Koch and Christian Kinch, states the company in a press release.

“The financing will enable the company to move to the next phase and will take us to an IPO in 2-3 years,” says Christian Kinch, Chairman and co-founder of SmartCella.

“I am very happy and proud that AMF is a shareholder in this exiting venture. I am especially happy that it is a very Swedish venture, based on research from Sweden, driven by Swedish entrepreneurs and funded by Swedish capital,” says Anders Oscarsson, Head of Equities, AMF.

Three business units

In the business unit Procella, the company is together with AstraZeneca developing a new way to regenerate those parts of the heart that have been damaged by a heart attack using cardiac progenitor cells.

The business unit Smartwise is developing a novel infusion micro-catheter, the Extroducer, for precise and localized administration of cells, drugs, RNA and other therapies. The Extroducer catheter was developed at the Karolinska Institutet for potential uses in cancer treatment and tissue regeneration in various organs.

The third business unit, SvedMed Solutions, works with developing novel methods for RNA-based therapies and methods for administration and delivery of such therapies.

“We are very pleased to have such a well renowned group of institutional and private investors join us as we now accelerate the development of Procella, Smartwise and SvedMed Solutions towards first-in-human studies, as well as to establish GMP manufacturing capabilities,” says Staffan Holmin, CEO, SmartCella.

Photo of Staffan Holmin, CEO, SmartCella